+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication



Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication



International Journal of Cancer 129(6): 1503-1510



Oncolytic herpes simplex virus (HSV) is currently in phase III clinical trials for development as a novel therapeutic agent against a broad range of human tumors. Although results have been promising, clinical outcome is likely to be compromised by intrinsic and acquired resistance to HSV replication, leading us to test agents that may overcome this obstacle. We found that, despite showing no effect on HSV replication in tumor cells fully permissive to the virus growth, the mTOR inhibitor rapamycin markedly increased the yield and dissemination of oncolytic HSVs in semipermissive tumor cells. Similar results were obtained in tumor-bearing mice. Co-administration of rapamycin with an HSV-derived oncolytic virus either blocked or reversed the growth of tumor xenografts established from semipermissive human tumor cells, while use of either agent alone produced only transient inhibitory effect. Together, our results suggest that rapamycin could be used to potentiate the activity of oncolytic HSVs against difficult-to-treat human tumors or perhaps to prevent the emergence of resistant tumor cells during virotherapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 055360386

Download citation: RISBibTeXText

PMID: 21128236

DOI: 10.1002/ijc.25808


Related references

Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells. Cell Cycle 8(14): 2194-2197, 2009

Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. American Journal of Cancer Research 6(2): 300-311, 2016

Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Research 67(16): 7850-7855, 2007

Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Human Gene Therapy 10(17): 2869-2878, 1999

Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Therapy 7(7): 1051-1059, 2000

RESTRICTION OF γ34.5-DELETED ONCOLYTIC HERPES SIMPLEX VIRUS REPLICATION IN GLIOBLASTOMA STEM-LIKE CELLS. Journal of Virology 2018, 2018

Axin expression enhances herpes simplex virus type 1 replication by inhibiting virus-mediated cell death in L929 cells. Journal of General Virology 94(Pt 7): 1636-1646, 2013

Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. Plos One 9(3): E92919, 2014

A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. Plos One 9(3): E93103, 2015

Herpes simplex virus replication in murine thymus derived and bone marrow derived cells and the ability of uv inactivated herpes simplex virus to activate endogenous c type virus in mouse lymphocytes. Abstracts of the Annual Meeting of the American Society for Microbiology 77: 286, 1977

Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Therapy 13(24): 1731-1736, 2006

Infection of human NT2 cells and differentiated NT-neurons with herpes simplex virus and replication-incompetent herpes simplex virus vectors. Journal of Neurovirology 7(1): 43-51, 2001

Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. International Journal of Cancer 132(7): 1592-1601, 2013

Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy. Journal of Virology 84(16): 8163-8171, 2010

Analysis of deoxy cytidine deaminase activity in herpes simplex virus infected or herpes simplex virus thymidine kinase transformed cells association with mycoplasma contamination not with virus infection. Journal of General Virology 57(1): 245-250, 1981